Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 52

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 52
---
 the participation in the purchase of a run -offinsurance policy for the Company’s executive officers, to be effective at the time of the Merger’s completion, with coverage amounts and terms to be approved by the Board of Directors, in each case for each of the financial year 2025 and the financial year 2026. 13.Approval of Contingent Value Rights (CVR) Agreement on an Advisory Basis Explanation:The Company intends to work towards selling its existing R&D assets under development, excluding the DOXA asset, as part of a contingent value rights agreement (the “ CVR Agreement”). The combined company intends to develop the DOXA R&D asset, which will remain with the combined company (both independently and in combination with the company’s diabetes product). The remaining assets of the Company are intended to be reorganized under the CVR Agreement for the purpose of being sold by a committee to be established specifically for this purpose and responsible for executing the sale. Shareholders of the Company, as they exist prior to the completion of the transactions contemplated by the Merger Agreement, are expected to be entitled to receive the net proceeds from the sale of the divested business, if and when it is sold, through mechanisms including Contingent Value Rights. It should be noted that if the divested business generates negative cash flow and/or profitability at the end of any fiscal quarter (except for intellectual property maintenance costs of up to $100,000 per calendar year), the combined company will have the right to cease the sale process of the divested business and take any action regarding it as deemed appropriate. Proposal:The Board of Directors proposes that the CVR Agreement be approved on an advisory basis. 14.Approval of Option and RSU Conversion on an Advisory Basis Explanation:The Company intends to convert outstanding options and RSUs issued by Kadimastem into equivalent securities with identical rights in the Company at the time of the completion of the transactions contemplated by the Merger Agreement (the “Conversions”). The NLS Common Shares underlying options and RSUs shall be transferred to a trustee and subsequently to the holder upon exercise of the option or once the entitlement to the share underlying the RSU arises. Proposal:The Board of Directors proposes that the Conversions be approved on an advisory basis. ******* [voting instructions and appendices follow] Voting Instructions: Please note the following instructions with respect to the participation in the extraordinary shareholders’ meeting: 1.Voting Rights Shareholders who are entered in the shareholder register maintained by our transfer Agent, VStock